Results 31 to 40 of about 21,216 (279)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +4 more sources

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

The Pediatric Infectious Disease Journal, 2021
We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and
Tom G. Jacobs, Koen J. van Aerde, A. Colbers, D. Burger   +3 more
semanticscholar   +1 more source

Drug-drug interactions with raltegravir

European Journal of Medical Research, 2009
Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj   +1 more source

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Cells, 2022
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study
Gaurav Kumar, Jacqueline Cottalorda-Dufayard, Rodolphe Garraffo, Francine De Salvador-Guillouët, Eric Cua, Pierre-Marie Roger   +5 more
doaj   +1 more source

Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed. [PDF]

Open Forum Infect Dis
Núñez I, Caro-Vega Y, MacDonald C, MacDonald C, Mosqueda-Gómez JL, Piñeirúa-Menéndez A, Matthews AA.   +6 more
europepmc   +3 more sources

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. [PDF]

, 2014
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).MethodsING116070 is an ongoing, single-arm, open-label ...
Chen, Shuguang, extended ING116070 study team, Letendre, Scott L, Mills, Anthony M, Min, Sherene S, Piscitelli, Stephen C, Song, Ivy H, Tashima, Karen T, Thomas, Deborah A   +8 more
core   +3 more sources

Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors [PDF]

, 2017
no abstract ...
Falasca, Francesca, Mazzuti, Laura, Mezzaroma, Ivano, Turriziani, Ombretta   +3 more
core   +1 more source

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Journal of Acquired Immune Deficiency Syndromes, 2020
BACKGROUND Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor (INSTI) available in a granule formulation suitable for use in neonates and ...
D. Clarke, E. Acosta, M. Cababasay, Jiajia Wang, A. Chain, H. Teppler, S. Popson, B. Graham, Betsy Smith, R. Hazra, Kat Calabrese, Y. Bryson, S. Spector, J. Lommerse, M. Mirochnick   +14 more
semanticscholar   +1 more source

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

Nephrology, Dialysis and Transplantation, 2020
BACKGROUND Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir.
E. Ndashimye, Mariano Avino, Abayomi S. Olabode, A. Poon, Richard Gibson, Yue Li, Adam Meadows, C. Tan, Paul S Reyes, C. Kityo, Fred Kyeyune, I. Nankya, M. Quiñones-Mateu, E. Arts   +13 more
semanticscholar   +1 more source